TERMS OF USE

Last updated: September 16, 2022

These Terms of Use (the "Terms of Use") govern and apply to your use of the www.Aequuspharma.com (the "Website") of Aequus Pharmaceuticals Inc. ("Aequus", "we", "us" or "our").

Please read these Terms of Use before using this Website. Your use of the Website is also subject to the provisions of Aequus's Privacy Notice. By using this Website you agree to these Terms of Use and you consent to the collection, use, storage, disclosure or processing of your personal information in accordance with the Privacy Notice. If you do not agree and consent, please do not use the Website.

Information on the Website

The Website is intended for informational purposes only and is provided solely on an "as is" and "as available" basis.

We use reasonable efforts to include accurate and up-to-date information on the Website. However, Aequus makes no warranties or representations as to the accuracy of the information. The Aequus assumes no liability or responsibility for any errors or omissions in the contents of this Website.

The Website may include general information and health-related information. The information provided on this Website is not a substitute for medical care. If you have, or suspect you have, a health problem, you should always consult with a licensed healthcare professional.

Aequus's Products

Products shown on the Website may not be available in all countries or may be known by a different name. Indications for use may vary from country to country. You should always check with a local qualified health care professional and read the Instructions for Use prior to use.

Data Privacy

Please read our Privacy Notice for information about the practices of Aequus with respect to the collection, use and disclosure of personal information. The collection, use and disclosure by the Aequus of personal information provided through this Website is subject to this Privacy Notice.

Copyright

All content, including but not limited to text, software, sound, photographs, video, graphics and other material contained on this website ("Content") is proprietary and protected by copyright and/or other intellectual property rights of the Aequus or its third-party licensors.

You may download, view, copy and print Content solely for personal non-public, informational purposes provided that any and all copyright, trademark and other intellectual property right notices appear on all copies, the Content is not modified or altered in any way and no graphics is used separate from the accompanying text. Any Content downloaded is at your own risk and you are solely responsible for any prejudice or damage resulting from the download of any such Content.

You may not use any Content in a manner that suggests an association with any of our products, services or marks. You may not add, delete, distort or misrepresent any content on the Website. You are not authorized to redistribute or sell the Content or to reverse-engineer, disassemble or otherwise convert it to any other form. Any attempts to defeat or circumvent any security features of the Website or Content are prohibited.

Other than as specifically stated above, you are not granted any right, title or interest in, or any license or authorization, to use this Website or any Content. Aequus disclaims any liability if your use of Content infringes the copyright or other intellectual property rights of third parties.

User feedback

Any feedback that you provide in relation to the Website or through the Website will be deemed to be non-confidential and non-proprietary, and the Aequus will be free to compile, use and redistribute the feedback for any purpose without restriction and without compensation to you.

Unsolicited ideas

To avoid potential misunderstandings and disputes, Aequus and its employees do not accept, review or consider unsolicited ideas, including but not limited to ideas for product enhancements, new products, services, technologies, processes, marketing strategies, product names or content ("Ideas").

If, despite our request to not send us your Ideas, you still submit them through this Website or to an email address contained herein, you agree that by the submission you assign, free of charge all worldwide rights, title and interest in your Idea and any related intellectual property rights to Aequus. Aequus has no obligation to review the Idea and no obligation to keep the Idea confidential.

Trademarks

"AEQUUS", is a trademark of Aequus, may not be used without written permission. All other trademarks, product names and company names or logos cited herein are the property of their respective owners.

Nothing contained in this website transfers any right, title or interest in or grants any license or consent to use any trademark, service mark or logo used on this website. Any rights not expressly granted herein are reserved.

Inappropriate Use

Any use of the Website for the purpose of sending, or to facilitate or encourage the sending of, unsolicited commercial electronic message or unsolicited bulk communications is prohibited. You are prohibited from using the Website in any manner that may violate the rights of any third party, including any privacy rights, or otherwise in violation of applicable law.

<u>Links</u>

This Website may include links to other websites that are not under the control of the Aequus. These links are offered for your convenience only. Aequus is not responsible for the content of such websites and shall not be liable for any damages or injury arising from the content of any other website.

Any link to this Website does not represent in any way, either explicitly or by implication, that the party linking to this Website has received the endorsement, sponsorship or support of the Aequus. Any hypertext link that you establish to this website must not state or imply any sponsorship or endorsement of your website by the Aequus and you may not incorporate any Content of this Website elsewhere.

Disclaimer

To the fullest extent permitted by applicable law, the Website and the Content are provided on an "as is" and "as available" basis. Aequus and their respective officers, directors, employees, agents, affiliates, suppliers, licensors, successors and assigns disclaim all warranties and conditions, express, implied, legal or statutory, including, but not limited to, implied warranties of title, quality, non-infringement, merchantable quality and fitness for a particular purpose, and expressly disclaim any representation or warranty that the Website will be free from errors, viruses or other harmful components, that the functionalities will be uninterrupted, that communications to or from the Website will be secure and not intercepted, or that the Content will be accurate, complete, current, adequate, or timely. To the fullest extent permitted by applicable law, in no event shall the Aequus be liable for any direct, indirect, incidental, consequential, special, exemplary, punitive or other damages (including, without limitation, damages for loss of data or profit, or due to business interruption) arising out of the use or inability to use the Website or the Content, even if advised of the possibility of such damage.

Changes, Termination or Suspension

Aequus may amend or modify these Terms of Use from time to time, without further notice to you, posting a revised version on the Website. Please check these Terms of Use regularly for any updates. Your continued use of the Website after any update is posted means that you accept those changes.

Aequus also reserves the right to delete, modify or supplement the content of this Website at any time, for any reason and at its sole discretion, without notice.

Aequus to terminate all or any part of this Website, or suspend your access to the Website, at any time without notice to you.

Governing law

This Website is intended for use by persons located in Canada only. If you use the Website from locations outside of Canada or the United States, you are responsible for compliance with applicable local laws.

To the full extent permitted by applicable law, these Terms of Use are governed by, construed and enforced in accordance with the laws of the Province of British Columbia, Canada, without reference to conflict of laws principles, and the federal laws of Canada applicable therein. Any dispute shall be submitted exclusively to the courts of competent jurisdiction in the Province of British Columbia, Canada.

Forward-looking information

Certain statements and information in this website includes forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "predict", "project", "potential", "continue", "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words and similar expressions.

Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements on the website include, but are not limited to, statements relating to:

- our ability to obtain funding for our operations, including funding for research and commercial activities;
- our ability to promote and market third-party products and the anticipated timing thereof, including our ability to successfully market Tacrolimus immediate-release ("Tacrolimus IR"), Vistitan™ ("Vistitan") and Evolve™ ("Evolve") in Canada;
- the expected benefits of Tacrolimus IR, Vistitan, Evolve and REV-0100;
- our estimates of the size and characteristics of the potential markets for Tacrolimus IR, Vistitan, Evolve and our internal product candidates;
- our business model and strategic plans;
- our ability to achieve profitability;
- our ability to establish and maintain relationships with collaborators with acceptable development,
 regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;
- whether we will be able to extend our current commercial relationships with third-party collaborators;
- our ability to expand commercial relationships with third-party collaborators to include additional products;
- whether our third-party collaborators will maintain their intellectual property rights in the technology we license;
- the manufacturing capacity of third-party manufacturers for our product candidates;
- the implementation of our business model and strategic plans;
- our ability to develop and commercialize product candidates;
- our commercialization, marketing and manufacturing capabilities and strategy;
- our ability to leverage internal capabilities and know-how;
- our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
- our expectations regarding federal, provincial, and foreign regulatory requirements;
- whether we will receive, and the timing and costs of obtaining, a development and commercial partner for our product candidates;
- whether we will receive, and the timing and costs of obtaining, regulatory approvals in the United States, Canada, the European Union, and other jurisdictions;
- the therapeutic benefits, effectiveness, and safety of our product candidates;
- the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates;
- the rate and degree of market acceptance and clinical utility of our future products, if any;
- whether our e-commerce and digital technology platform will result in greater access to or benefit eyecare professionals;
- the timing of, and our ability and our collaborators' ability, if any, to obtain and maintain regulatory approvals for our product candidates;
- our expectations regarding market risk, including interest rate changes and foreign currency fluctuations;
- our ability to engage and retain the employees or consultants required to grow our business;

- the compensation that is expected to be paid to employees and consultants of the Company;
- our future financial performance, projected expenditures, and ability to make investments;
- our expectations regarding the use of proceeds from the Company's investments, including investments in reVision Therapeutics, Inc. ("reVision") and REV-0100;
- developments relating to our competitors and our industry, including the success of competing therapies that are or become available;
- estimates of our expenses, future revenue, capital requirements and our needs for additional financing;
- our ability to repay the Loan (as defined herein), which Loan may become payable at any time on demand;
- the revocation of the failure-to-file cease trade order by the BCSC (as defined herein);
- our ability to advance product candidates into, and successfully complete, clinical trials; and
- our ability to recruit enough patients for our future clinical trials.

Many factors could cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. All forward-looking statements, including those not specifically identified herein, are made subject to cautionary language above and on subsequent pages. Readers are advised to refer to the cautionary language when reading any forward-looking statements.

Such forward-looking statements reflect our current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies.

In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors, including "Risk Factors" listed in the Company's most recent Annual Information Form filed on SEDAR (www.sedar.com).